GlaxoSmithKline (NYSE: GSK) reported Q3 EPS of GBP0.36, better than the analyst estimate of GBP0.33. Revenue for the quarter came in at GBP8.1 billion versus the consensus estimate of GBP8.01 billion.

• Now expect 2018 Adjusted EPS growth of 8-10% CER

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.